Cytori is committed to developing and commercializing specialty therapeutics.
Since 2002, Cytori has enabled researchers and clinicians to study and administer cell therapies using our novel Celution® System platform which harnesses the potential of stem and regenerative cells from adipose tissue.
In 2017, Cytori strengthened its specialty therapeutics position by acquiring a nanomedicine platform technology that combines widely-known and prescribed chemotherapy agents, doxorubicin and docetaxel, both with liposomal encapsulation technology.
This marriage of technologies has the potential to improve patient care for both life-debilitating and life-threatening conditions and diseases.
Cytori Therapeutics, Inc. is dedicated to enhancing lives through the development of novel therapeutics. To realize this mission, Cytori defines, develops, and delivers specialty therapeutics that address poorly met market and medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we strive to deliver meaningful results that create exceptional value for patients, customers, partners, employees, shareholders, and society.
- We do what is right, deliver what we promise and own the outcome.
- We place our patients and customers at the heart of everything we do.
- We thoughtfully balance competing priorities to achieve important results.
- We are an agile company that embraces big challenges.
- We value spirited communication and care about one another.
At the end of 2016, Cytori had 65 full-time employees based in Japan, the United Kingdom, and the United States. These employees are deployed across the following functional areas and many hold advanced PhD and MD degrees:
- 31 – research and development
- 18 – management, finance, and administration
- 9 – sales and marketing
- 7 – manufacturing
Cytori plans to grow its organization, particularly in its San Antonio location, in support of its recently acquired nanomedicine assets.
In 2013, Cytori granted Bimini Technologies a global exclusive license to Cytori Cell Therapy technology for hair applications. Through Kerastem, its wholly owned subsidiary, Bimini Technologies is conducting a FDA-approved Phase II clinical trial in the U.S. called STYLE.
For parties interested in licensing Cytori Cell Therapy™ or Cytori Nanomedicine™ technologies, please contact us at BusinessDevelopment@cytori.com .